Brokerages Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) Target Price at $18.42

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been given an average rating of “Moderate Buy” by the seven ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $18.42.

Several equities research analysts have recently issued reports on the stock. Stifel Nicolaus reissued a “hold” rating and set a $14.00 price objective (up previously from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. Jefferies Financial Group raised ALX Oncology from a “hold” rating to a “buy” rating and lifted their price target for the company from $8.00 to $18.00 in a research note on Friday, December 8th.

ALX Oncology Stock Performance

ALXO stock opened at $11.41 on Friday. ALX Oncology has a 1-year low of $3.94 and a 1-year high of $17.42. The business’s 50-day moving average price is $14.15 and its two-hundred day moving average price is $11.10. The firm has a market cap of $572.23 million, a PE ratio of -3.04 and a beta of 1.63. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.05.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.09). As a group, research analysts forecast that ALX Oncology will post -3.33 earnings per share for the current year.

Insider Transactions at ALX Oncology

In related news, CEO Jason Lettmann bought 4,400 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were acquired at an average price of $11.31 per share, for a total transaction of $49,764.00. Following the completion of the acquisition, the chief executive officer now owns 171,620 shares of the company’s stock, valued at approximately $1,941,022.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Jason Lettmann bought 4,400 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were acquired at an average cost of $11.31 per share, for a total transaction of $49,764.00. Following the completion of the acquisition, the chief executive officer now owns 171,620 shares in the company, valued at $1,941,022.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Shelly Pinto sold 2,717 shares of the stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $13.60, for a total transaction of $36,951.20. Following the completion of the sale, the chief accounting officer now owns 78,591 shares of the company’s stock, valued at approximately $1,068,837.60. The disclosure for this sale can be found here. Company insiders own 50.30% of the company’s stock.

Hedge Funds Weigh In On ALX Oncology

A number of institutional investors have recently bought and sold shares of ALXO. Swiss National Bank boosted its stake in shares of ALX Oncology by 8.5% during the 1st quarter. Swiss National Bank now owns 19,200 shares of the company’s stock worth $324,000 after acquiring an additional 1,500 shares during the period. JPMorgan Chase & Co. lifted its holdings in ALX Oncology by 21.6% during the 1st quarter. JPMorgan Chase & Co. now owns 19,237 shares of the company’s stock valued at $326,000 after purchasing an additional 3,417 shares during the last quarter. MetLife Investment Management LLC boosted its position in ALX Oncology by 58.5% during the first quarter. MetLife Investment Management LLC now owns 10,745 shares of the company’s stock worth $182,000 after purchasing an additional 3,965 shares during the period. BlackRock Inc. increased its holdings in shares of ALX Oncology by 1.1% in the first quarter. BlackRock Inc. now owns 1,355,478 shares of the company’s stock valued at $22,907,000 after purchasing an additional 14,907 shares during the last quarter. Finally, Federated Hermes Inc. bought a new position in shares of ALX Oncology in the first quarter valued at about $914,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.